Cardiox

Early Stage Partners led the Series B round of investment in this company, which is commercializing a non-invasive method for detecting the presence of a right-to-left cardiac shunt, known as Patent Foramen Ovale (PFO), to enable closure before the occurrence of a debilitating or life threatening stroke.

Find Out More About ESP